[go: up one dir, main page]

AR030345A1 - Metodo de tratamiento de desordenes relacionados con angiogenesis - Google Patents

Metodo de tratamiento de desordenes relacionados con angiogenesis

Info

Publication number
AR030345A1
AR030345A1 ARP010103846A ARP010103846A AR030345A1 AR 030345 A1 AR030345 A1 AR 030345A1 AR P010103846 A ARP010103846 A AR P010103846A AR P010103846 A ARP010103846 A AR P010103846A AR 030345 A1 AR030345 A1 AR 030345A1
Authority
AR
Argentina
Prior art keywords
angiogenesis
disorders related
treatment
derivatives
macular degeneration
Prior art date
Application number
ARP010103846A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR030345A1 publication Critical patent/AR030345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe el uso de ácidos 3-benzoilfenilacéticos y derivados, incluyendo nepafenac, para el tratamiento de desordenes relacionados con angiogénesis , incluyendo desordenes relacionados con angiogénesis oftálmicos tales como retinopatía diabética y degeneracion macular exudativa.
ARP010103846A 2000-08-14 2001-08-10 Metodo de tratamiento de desordenes relacionados con angiogenesis AR030345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22513300P 2000-08-14 2000-08-14

Publications (1)

Publication Number Publication Date
AR030345A1 true AR030345A1 (es) 2003-08-20

Family

ID=22843668

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103846A AR030345A1 (es) 2000-08-14 2001-08-10 Metodo de tratamiento de desordenes relacionados con angiogenesis

Country Status (18)

Country Link
US (1) US20020037929A1 (es)
EP (1) EP1309323B1 (es)
JP (2) JP5586117B2 (es)
KR (1) KR20030017653A (es)
CN (1) CN1447688A (es)
AR (1) AR030345A1 (es)
AT (1) ATE345123T1 (es)
AU (2) AU8333701A (es)
BR (1) BR0113204A (es)
CA (1) CA2417282C (es)
DE (1) DE60124560T2 (es)
DK (1) DK1309323T3 (es)
ES (1) ES2275710T3 (es)
MX (1) MXPA03001057A (es)
PL (1) PL366220A1 (es)
PT (1) PT1309323E (es)
WO (1) WO2002013804A2 (es)
ZA (1) ZA200300782B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
KR20050043923A (ko) * 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
CA2504460A1 (en) * 2002-11-12 2004-05-27 Peter G. Klimko Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
DE122011100019I1 (de) 2003-01-21 2011-11-03 Senju Pharma Co Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
PL1809270T3 (pl) * 2004-11-09 2010-08-31 Alcon Inc Kwas 5,6,7-trihydroksyheptanowy i jego analogi do leczenia chorób oczu i chorób związanych z odpowiedziami hiperproliferacyjnymi i angiogenicznymi
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
US20100292289A1 (en) * 2007-11-30 2010-11-18 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with novel amides
KR20100135748A (ko) * 2008-02-21 2010-12-27 센주 세이야꾸 가부시키가이샤 아쥬반트로서의 안과용 ｎｓａｉｄ
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577461A5 (es) * 1975-08-13 1976-07-15 Robins Co Inc A H
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
KR100732262B1 (ko) * 1999-10-21 2007-06-25 알콘, 인코퍼레이티드 약물 전달 장치
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU1051201A (en) * 1999-11-11 2001-06-06 Wireless Methods Ltd. Remote switching and actuation of electrical devices

Also Published As

Publication number Publication date
AU8333701A (en) 2002-02-25
DK1309323T3 (da) 2007-03-19
ES2275710T3 (es) 2007-06-16
DE60124560T2 (de) 2007-09-06
WO2002013804A2 (en) 2002-02-21
PL366220A1 (en) 2005-01-24
US20020037929A1 (en) 2002-03-28
MXPA03001057A (es) 2004-09-10
JP2004520267A (ja) 2004-07-08
JP2012193214A (ja) 2012-10-11
HK1057331A1 (en) 2004-04-02
DE60124560D1 (de) 2006-12-28
WO2002013804A3 (en) 2002-06-06
AU2001283337B2 (en) 2006-06-15
KR20030017653A (ko) 2003-03-03
JP5586117B2 (ja) 2014-09-10
BR0113204A (pt) 2006-02-21
EP1309323A2 (en) 2003-05-14
ZA200300782B (en) 2004-08-27
CN1447688A (zh) 2003-10-08
PT1309323E (pt) 2007-01-31
ATE345123T1 (de) 2006-12-15
CA2417282C (en) 2009-12-22
CA2417282A1 (en) 2002-02-21
EP1309323B1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
UY28126A1 (es) Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
HN1999000124A (es) Derivados de pirazol substituido.
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
UY27878A1 (es) Derivados de indolinfenilsulfonamida
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
PA8651301A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
BRPI0510778B8 (pt) composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
DK1343472T3 (da) Thixotropisk næsespray
AR030346A1 (es) Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
AR035600A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 en la fabricacion de medicamentos para tratar la disfuncion sexual
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.

Legal Events

Date Code Title Description
FC Refusal